Overview

Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection

Status:
Active, not recruiting

Trial end date:
2022-05-01

Target enrollment:

Participant gender:

Summary

This is a non-randomized, a single arm, phase II multicentre study of sofosbuvir plus ledipasvir (genotype 1 and 4) or sofosbuvir plus velpatasvir (genotype 2 and 3) for patients with hepatitis C virus-associated indolent B-cell lymphomas (HCV-RNA positive).

Phase:

Phase 2

Details

Lead Sponsor:

Fondazione Italiana Linfomi ONLUS

Treatments:

Ledipasvir
Ledipasvir, sofosbuvir drug combination
Ribavirin
Sofosbuvir
Velpatasvir